Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Big Technologies firmly rejects claims made by ex-CEO

(Sharecast News) - Big Technologies published a letter to shareholders on Friday, firmly rejecting allegations made by former chief executive officer Sara Murray in correspondence sent to certain investors earlier in the week. In a statement, the company said the letter, which was now available on its website alongside amended High Court legal filings, set out its formal response to Murray's criticisms.

Big Technologies reiterated that it "rejects in the strongest terms" the allegations contained in the former CEO's 8 June letter.

The dispute formed part of ongoing legal proceedings brought by the company against Murray and others, with amended particulars of claim recently filed in the High Court.

Big Technologies said it would continue to pursue its claims vigorously and stressed that the board had acted, and would continue to act, in the best interests of the company and its shareholders.

The board also reaffirmed its unanimous support for all resolutions proposed at the upcoming 2025 annual general meeting, recommending shareholders vote in favour.

Directors intended to back the resolutions with their own shareholdings, and said they remained available to engage with investors ahead of the AGM.

At 1446 BST, shares in Big Technologies were down 2.55% at 91.8p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.